InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: None

Sunday, 07/23/2017 7:08:07 PM

Sunday, July 23, 2017 7:08:07 PM

Post# of 2099
Also, just for conversational purposes. Anyone familiar with KB (Katherine Barnett) Peters? She works in the Neuro-Onc dept at Duke and published this research.

Look who is funding her research.

http://www.tandfonline.com/doi/full/10.1080/21678707.2016.1235971

Utilizing PubMed and MEDLINE® databases, we identified key preclinical and clinical data pertaining to VB-111. We then reviewed ClinicalTrials.gov to determine the status of ongoing research.

Expert opinion: Demonstrating safety and showing signs of efficacy in early phase clinical trials, VB-111 is being studied in combination with and without bevacizumab in a large phase 3 trial for recurrent glioblastoma. Given the data, VB-111 is a unique viral-mediated, antiangiogenic approach that has significant potential to make an impact in the field of oncology and neuro-oncology. We agree with the continued study of this agent in expanded and randomized cohorts to determine if VB-111 can indeed impact survival in glioblastoma.

KEYWORDS: VB-111, virotherapy, angiogenesis, adenovirus, glioblastoma, glioma
Additional information

Funding

KB Peters research is funded by Eisai, Merck, Genentech, Amgen, BioMimetix Pharmaceutical, Inc., VBL Therapeutics and Agios.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News